Explore more publications!

Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on October 18, 2025

JointCommerce Launches A21+ ‘Household Targeting’ Solution for Connected TV Video Advertising
Barry I. Gold to Present Groundbreaking ‘We’re Overdosed’ Series at Frankfurt Buchmesse 2025
A Million Thanks Launches New Veteran Letter Request Program for Post-9/11 Veterans
Nirvana Recovery’s Integrated Model Leads Arizona’s Alcohol Fight
Dr. Kaushal Kakkad Honored with Doctor of Philosophy in Marketing and Innovation by Kennedy University
Evoq Technologies’ Breakthroughs in Retinal Diagnostics at AAO Annual Meeting
New Book: Experiencing Transcendence Reimagines Addiction & Trauma Recovery Moving Beyond Lifelong Struggle to Freedom
The Untold Story of America’s Opioid Epidemic Uncovers the Truth Behind the Crisis
KFSHRC Redefines Cancer Care Through Precision, Innovation, and Localized Advanced Therapies
Rozelle’s Soothing Care Dental Earns QIP Accreditation for Outstanding Practice Standards
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
 Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions